Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) Enterprise Value: 2023-2025

Historic Enterprise Value for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $21.7 million.

  • Tonix Pharmaceuticals Holding's Enterprise Value rose 187.04% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$334.1 million, marking a year-over-year decrease of 446.63%. This contributed to the annual value of -$37.1 million for FY2024, which is 142.15% down from last year.
  • Tonix Pharmaceuticals Holding's Enterprise Value amounted to $21.7 million in Q3 2025, which was down 84.28% from $138.2 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Enterprise Value peaked at $138.2 million during Q2 2025, and registered a low of -$39.1 million during Q1 2023.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Enterprise Value had a median value of -$9.3 million in 2023 and averaged $1.4 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 1,002.27% in 2024, then surged by 6,764.69% in 2025.
  • Tonix Pharmaceuticals Holding's Enterprise Value (Quarterly) stood at -$15.3 million in 2023, then tumbled by 142.15% to -$37.1 million in 2024, then skyrocketed by 187.04% to $21.7 million in 2025.
  • Its last three reported values are $21.7 million in Q3 2025, $138.2 million for Q2 2025, and -$16.7 million during Q1 2025.